Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations

Some subgroups of patients with advanced/metastatic non-small-cell lung cancer (NSCLC) are frequently considered ineligible for the aggressive, platinum-based combination chemotherapy that is the recommended treatment. Elderly patients may have a poorer tolerance of chemotherapy due to impaired orga...

Full description

Saved in:

Bibliographic Details
Main Authors:	Stahel, R, Rossi, A, Petruzelka, L, Kosimidis, P, de Braud, F, Bernardo, M M, Souquet, P-J, Parra, H Soto, Gridelli, C
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group 2003
Subjects:	Original Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2750243/ https://ncbi.nlm.nih.gov/pubmed/14661049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601479
Tags:	Add Tag No Tags, Be the first to tag this record!

Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations

Similar Items